• About BAYCELLator
  • Projects
      Project 1
        Project 2
          Project 3
            Project 4
              Project 5
                Project 6
                  Project 7
                    Project 8
                  • Publications
                  1. The Bavarian Cell Therapy Catalyst
                  2. Projects
                  3. Project 7

                  Project 7

                  Generation of hypoimmunogenic TCR or CAR cells from induced pluripotent stem cells

                  Academic Partner
                  Prof. Dr. med. Dirk H. Busch
                  Institut für Medizinische Mikrobiologie und Hygiene - TUM. Deputy Spokesman BAYCELLator
                  publications
                  more on the person
                  Industry Partner
                  Dr. Mine Bakar
                  Repairon Immuno
                  Collaborators

                  Prof. Dr. med. Sebastian Kobold

                  Abt. Klinische Pharmakologie, Klinikum der Universität München

                  Prof. Dr. med. Michael von Bergwelt 

                  Medizinische Klinik III, KUM

                  Prof. Dr. med. Michael Hudecek 

                  Medizinische Klinik II, UKW

                  PD Dr. rer. nat. Thomas Nerreter 

                  Medizinische Klinik II, UKW

                  Project Summary

                  Chimeric antigen receptor-based immunocellular therapy has emerged as a groundbreaking advancement in the field of cancer treatment. Despite delivering remarkable clinical outcomes, therapies that rely on a patient's own cells face limitations due to extended manufacturing times, high costs, and the challenge of procuring an adequate number of cells from individuals who have undergone multiple rounds of prior chemotherapy. Off-the-shelf or allogeneic CAR cell products offer promising alternatives to address these associated challenges. Induced pluripotent stem (iPS) cells present a highly favorable cell source for cellular therapies, thanks to their unlimited capacity for proliferation, ease of genetic modification, and their ability to differentiate into immune cells, including T and NK cells. In the collaborative Baycellator project between TUM and Repairon Immuno, our shared objective is the development, production, and commercialization of iPS cell-derived immune cell products for innovative therapeutic solutions.

                  Project related publications

                  1. Rosenberg, S.A. and N.P. Restifo, Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 2015. 348(6230): p. 62-8.

                  2. Iriguchi, S. and Kaneko, S., Toward the development of true "off-the-shelf" synthetic T-cell immunotherapy. Review Cancer Sci, 2019. 110(1):16-22.

                  3. Li, Y. et al., Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell, 2018. 23(2):181-192.

                  Contact Details

                  Klinikum der Universität München. Abteilung Klinische Pharmakologie 

                  Lindwurmstrasse 2a
                  80337 München
                  +49 089 4400 57322 Klinische Pharmakologie, KUM

                  Supported by the Bavarian Research Foundation - Bayerische Forschungsstiftung

                  Contact Form

                  I agree to the data usage notice (see below). *

                  Security question (I'm not a robot!)

                  Data Usage Notice

                  Your personal data will be treated confidentially by us and will only be used to contact you by e-mail, telephone and/or in writing as part of this contact. Your information will be adequately protected against access by third parties and collected, processed and used in accordance with the provisions of the Federal Data Protection Act. The provision of your personal data, in particular your data on your health, is voluntary. If necessary, your request will be forwarded to the responsible departments or persons within the Munich University Hospital (KUM). In this context, there is the possibility that non-medical staff of the clinic may gain knowledge of the information you have disclosed. This information will not be passed on or transmitted to third parties outside the clinic. Your data will be deleted no later than 3 months after your information has been evaluated or forwarded to the responsible office. You can revoke your consent to the earmarked processing and use of the data at any time in writing without giving reasons. Your stored data will then be deleted immediately within the framework of legal regulations. The relevant information about your request will be sent or forwarded to you in unencrypted form at the email address you provided, without providing any information about your health. This poses a risk under data protection law. We will only send requested patient and personal application documents to a reasonable extent by post if you have given your postal address. Please also note our general data protection declaration

                  Login for editors
                  Imprint | Data-Safety

                  The Bavarian...

                  • About BAYCELLator
                  • Projects
                    • Project 1
                    • Project 2
                    • Project 3
                    • Project 4
                    • Project 5
                    • Project 6
                    • Project 7
                    • Project 8
                  • Publications